Dr1 is a general negative regulator of class II and class III gene expression (1, 2). It binds to the basic repeat domain of TBP on promoter DNA and can prevent the RNA polymerase II holoenzyme, or its TFIIB and/or TFIIA subunits, from assembling into an initiation complex (3, 4). Dr1 is phosphorylated in vivo and this modification affects its interaction with TBP (1). In addition, Dr1 interacts with the hyperphosphorylated form of Pol II and with the repression domain of the AREB6 repressor (5, 6). Dr1 forms a heterodimer complex with DRAP1 through its histone fold domain (7). More recently it was discovered that Dr1-DRAP1 is a bi-functional basal transcription factor that differentially regulates gene transcription through DPE (downstream promoter elements) or TATA box motifs (8). It can stimulate transcription in vitro from Drosophila promoters containing DPEs, whereas it represses transcription from TATA-containing promoters (8).

Each vial contains 100 μg IgG in 0.1 ml of PBS.

Specificity
α-DR1 reacts with the DR1 protein in HeLa nuclear extract by Western Blotting. Recommended dilution range for Western blot analysis: 1:2000-1:5000. Recommended starting dilution: 1:2000.

Storage
Aliquot and store at –20°C.

References:
1. Inostroza, J.A., et al., (1992) Cell 70, 477-489
2. White, R.J., et al., (1994) Science 266, 448-451
3. Mermelstein, F., et al., (1996) Genes Dev. 10, 1033-1048
4. Kim, T.K., et al., (1995) J. Biol. Chem. 270, 10976-10981
5. Castano, E., et al., (2000) Proc. Natl. Acad. Sci. USA 97, 7184-7189
6. Ikeda, K., et al., (1998) Mol. Cell. Biol. 18, 10-18
7. Goppelt, A., et al., (1996) EMBO J. 15, 3105-3116
8. Willy, P. J., et al., (2000) Science 290, 982-985

DISCLAIMER

This products is recommended For RESEARCH USE ONLY and is Not qualified for Use in Diagnostic or Therapeutic Procedures.